SCHEMBL16610876

SCHEMBL16610876

COc1nccc2c1c(-c1ccc(N3CCOCC3)cc1)nn2C1CCCCC1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.41
LRRK2 Q5S007 2/20 0.40
GSK3B P49841 1/20 0.38
MERTK Q12866 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CASP1 P29466 3/20 0.37
CASP7 P55210 3/20 0.37
MEN1 O00255 2/20 0.37
CYP1A2 P05177 2/20 0.37
KMT2A Q03164 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TSHR P16473 1/20 0.37
ALOX5 P09917 2/20 0.36
PRKDC P78527 2/20 0.36
KCNH2 Q12809 1/20 0.36
FYN P06241 1/20 0.36
CFTR P13569 1/20 0.36
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35
SYK P43405 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16611339 0.83 LRRK2 (0.39) LRRK2GSK3BALDH1A1CASP1CASP7
SCHEMBL16611010 0.81 LRRK2 (0.38) LRRK2GSK3BMERTKALDH1A1CASP1
SCHEMBL16610837 0.80 LRRK2 (0.44) LRRK2GSK3BALDH1A1CASP1CASP7
SCHEMBL16610962 0.74 MAP4K1 (0.41) LRRK2GSK3BALDH1A1CASP1CASP7
SCHEMBL16610911 0.74 TSHR (0.41) LRRK2GSK3BALDH1A1CASP1CASP7
SCHEMBL16611322 0.70 TBK1 (0.43) LRRK2GSK3BPRKDCKCNH2JAK2
SCHEMBL16610949 0.70 LRRK2 (0.74) LRRK2
SCHEMBL16610902 0.69 EGFR (0.46) MERTKPRKDCKCNH2
SCHEMBL16611225 0.69 TGFBR1 (0.42) LRRK2MERTKPRKDCJAK2
SCHEMBL16611763 0.69 CCNA2 (0.43) LRRK2GSK3BALDH1A1PRKDCMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 SLC18A3 4816/4885LRRK2 1393/4885GSK3B 3280/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 SLC18A3 4816/4885LRRK2 1393/4885GSK3B 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.